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TransformationTranscription from the major upstream early gene promoter, P89, of bovine papillomavirus (BPV)-1 is
detectable in transfected cells lacking viral gene products yet also responds to viral E2 proteins. In contrast to
human papillomaviruses (HPVs), the BPV upstream regulatory region (URR) functions as a transcriptional
enhancer in epithelial cells and ﬁbroblasts of bovine, murine or human origin. Mutations of Sp1 and/or two
novel transcriptional enhancer factor (TEF)-1 sites within the 5′ URR of the intact BPV-1 genome
dramatically reduced P89-initiated mRNA levels, leading to decreased BPV-1 plasmid ampliﬁcation and
inefﬁcient formation of transformed cell foci. However, cell lines transformed with wt or mutant BPV-1
genomes contained similar levels of unintegrated BPV-1 DNA, P89 mRNA and E2-dependent transactivation.
We conclude that cellular factors necessary for activating viral early gene transcription, establishment of viral
plasmid replication and cell immortalization are not required during the maintenance phase of BPV-1
infection.
Published by Elsevier Inc.IntroductionPapillomaviruses induce a wide range of epithelial neoplastic
growths ranging from benign papillomas or warts to invasive cancers
in humans and animals. In all known cases, infection with mucosal
and cutaneous human papillomavirus (HPV) strains is restricted to
epithelial cells of the skin, mucosa or their adnexa. In contrast, some
animal papillomaviruses cause ﬁbropapillomas, that is, warts com-
prising an underlying proliferation of dermal ﬁbroblasts which also
harbor persistent viral plasmid genomes. The most extensively
studied model, bovine papillomavirus (BPV) type 1, is an example
(see Lambert, 1991; Turek et al., 1987 and DiMaio, 1991 for review).
In accord with BPV-1's ability to infect dermal ﬁbroblasts in vivo,
BPV-1 virions or recombinant BPV-1 DNA can neoplastically transform
bovine or rodent ﬁbroblasts in which the viral genome persists as
unintegrated, supercoiled circular BPV-1 plasmids (Dvoretzky et al.,
1980; Lancaster, 1981; Law et al., 1981; Lowy et al., 1980). Cell
transformation absolutely depends on the continued expression of at
least some viral genes because ﬁbroblasts that have lost BPV-1University of Iowa College of
. Fax: +1 319 339 7178.
ugen).
Inc.genomes due to interferon treatment revert to the nontransformed
phenotype (Turek et al., 1982).
The regulation of BPV-1 early gene expression is still incompletely
understood yet it is apparent that it differs from that of mucosal HPVs
in several important aspects. Early gene transcripts of mucosal HPVs
as well as BPV-1 start at a major promoter immediately upstream of
the E6 gene, termed P89 or P2 in BPV-1 (Baker and Howley, 1987;
Choe et al., 1989; Stenlund et al., 1985; Szymanski and Stenlund,1991).
In mucosal HPVs, the E6 promoter of HPV types 16 or 31 is one of the
promoters active early after viral genome introduction into epithelial
cells by transfection (Lace et al., 2008a) and in persistently infected
basal keratinocytes; additional promoters are activated only during
late stages of infection in differentiating keratinocytes (Meyers et al.,
1992; Ozbun and Meyers, 1998). In contrast, BPV-1 early gene
transcripts originate at three other promoters, P890 (P3), P2443
(P4) and P3080 (P5) in addition to the P89 promoter early after
genome introduction in persistently infected ﬁbroblasts (Szymanski
and Stenlund, 1991).
Unlike more complex viral organisms, such as herpesviruses,
papillomavirus particles do not include viral gene products, such as
the E2 transactivator (E2-TA), that regulate viral gene expression and
replication. Therefore, their immediate early transcription is entirely
dependent on cellular factors. Mucosal HPVs have complex, cell type-
dependent enhancers in their upstream regulatory regions (URRs)
Fig. 1. The BPV-1 P89 promoter is activated by cellular factors in the absence of E2. BPV-1 fragments containing the P89 promoter were linked to the cat gene. The relative activity of
the constructions was compared to the minimal P89 promoter in pP89-cat (nt 1–99; clone i) in mouse NIH-3T3 ﬁbroblasts transiently cotransfected with a control plasmid (pMSV-
neo) or with a clone expressing the full-length BPV-1 E2 protein (pMSV-E2). The baseline (+MSV-neo) activity of pP89-cat (“i”) was ∼5-fold lower than that of the enhancer-
negative SV40 early promoter in pSVE-cat (not shown). Shaded box represents the BPV enhancer while the open diamonds represent the E2 binding sites (illustrated in the ﬁrst
sequence).
Fig. 2. BPV-1 P89 transcription is activated by cellular trans-acting factors interacting
with the URR. (A) Diagram of BPV-1 P89 promoter constructs, antisense RNA probes
and predicted hybridized, protected RNA fragments. (B) RNA was extracted from NIH-
3T3 cells 24 h after transfection with 18 μg of the indicated P89 reporter clones, 8 μg
RSV-E2 or RSV-neo, and 1 μg pSV2N-cat(Δ13), hybridized to uniformly 32P-labeled
antisense probes extending to nt 7902, digested with RNase, and the resulting double-
stranded RNA fragments were resolved by gel electrophoresis adjacent to molecular
weight markers (not shown). The protected bands of 91 nt for P89 and 56 nt for the
internal cat control transcripts are shown by the arrows.
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1990; Cripe et al., 1987; Gius et al., 1988; Gloss et al., 1987; Rando et al.,
1986; Swift et al., 1987). The HPV enhancers are active in keratino-
cytes, cervical carcinoma cells and in some epithelial tumor cell lines,
but do not function well in ﬁbroblasts (Cripe et al., 1990). Cell type-
speciﬁc activation of viral transcription thus correlates with the host
range of HPV infection restricted to mucosal and cutaneous keratino-
cytes and related cells (see Bernard and Apt, 1994; Turek and Smith,
1996 for reviews).
In BPV-1, weak E2-independent enhancer activity was localized to
a short segment in the distal part of the URR (Stenlund and Botchan,
1990; Stenlund et al., 1987; Vande Pol and Howley, 1990) and
observed to activate the E2-TA-coding P2443 promoter (Spalholz et
al., 1991; Szymanski and Stenlund, 1991). Deletion of the enhancer
abrogated cellular transformation as well as BPV-1 DNA replication in
ﬁbroblasts but these activities could be restored by E2-TA (Vande Pol
and Howley,1992). This observation had suggested that the distal URR
enhancer activates E2-TA expression from P2443, which in turn
triggers the transcription of other viral early genes from P89 and other
BPV promoters.
Nevertheless, other early promoters including P89 also are active
in the absence of E2-TA. The BPV-1 URRwas found to substitute for the
promoter of thymidine kinase (tk) gene in cis, presumably by
initiating tk transcription from P89 (Campo et al., 1983). Furthermore,
P89 as well as other BPV early gene promoters are active in ﬁbroblasts
transfected with a BPV-1 E2 mutant (Szymanski and Stenlund, 1991).
Taken together, these observations indicate that, similar to HPV major
early promoters, transcription at the P89 promoter of BPV-1 is also
activated by cellular factors. In contrast to HPVs, BPV-1 is transcrip-
tionally active in ﬁbroblasts in addition to keratinocytes and thus
exhibits an extended host cell type range. We have deﬁned the
enhancer activity of the BPV-1 URR in greater detail, focusing on the
contribution of cellular transcription factors to the broader BPV-1 cell
type speciﬁcity and on its role in neoplastic transformation and viral
persistence.
Results
Regulatory cis elements of the BPV-1 URR
While deﬁning E2-dependent trans-activation (Haugen et al.,
1987; Haugen et al., 1988), we observed that a BPV-1 P89 promoter
fragment, extending ∼1500 nt upstream of the transcription start
site, had detectable activity in the absence of the E2 transactivator in
transfected mouse C127I and NIH-3T3 ﬁbroblasts. To map the cis
elements of the P89 promoter responsible for its E2-independentactivity, we constructed a set of plasmids containing parts of the 5′
cis sequences of P89 linked to the cat reporter gene (Fig. 1). The
resulting pP89-cat constructions were cotransfected into uninfected
NIH-3T3 cultures together with either a control plasmid (column
“+pMSV-neo”) or a clone expressing the BPV-1 E2 transactivator
(column “+pMSV-E2”).
P89 promoter activity in the absence of E2 required cis sequences
between nt 7143 and the transcription start site (Fig. 1, clones a–c).
Deletions in sequences between nt 7143 and nt 7351 (Fig. 1, clones d–
g, i) greatly reduced cell-dependent P89 activity. Clone i represents
the minimal P89 promoter containing its 5′ CCAAT and TATAA
elements [BPV-1 nt 1–99 (Linz and Baker, 1988)]. The upstream
fragment between nt 7142 and 7477 was sufﬁcient to activate the P89
promoter by cellular factors (Fig. 1, clone h). This fragment
encompasses the previously described enhancer element within the
P7185 promoter (Stenlund and Botchan, 1990; Stenlund et al., 1987;
Vande Pol and Howley, 1990). In contrast, all P89 clones containing
multiple E2-binding ACC(N)6GGTmotifs were highly stimulated by E2
Fig. 3. BPV-1 URR sequences 5′ to P89 contain multiple active cis elements. BPV-1 URR
fragments were linked either upstream (panel A) or downstream (panel B) from the
enhancer-negative SV40 early promoter-driven cat gene in the pSVE-cat reporter clone.
The shaded boxes indicate BPV fragments in the inverted orientation within the SV40
construct. Relative activities are expressed as fold above the parental pSVE-cat plasmid
in duplicate transiently transfected cultures of NIH-3T3 cells in two to four independent
assays and is listed numerically next to the schematic for each plasmid construct.
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enhancer but lacks most of the E2 motifs retained only ∼10% of the E2
response. The cell-dependent cis sequences were therefore distinct
from the E2 response elements.Table 1
Activity of the BPV-1 P89 promoter and its cis elements in different cell types.
Reporter construct BPV-1 sequences Transfected cellsa
Bovine Murine
Fibroblast Epithelial Fibroblast Terato
B1 BMGE 3T3 F9
Promoter clones
Xba-P89 cat 6133–99 10.5 6.7 39.7 1.1
Bgl-P89 cat 6946–99 nd nd 17.8 2.3
Cla-P89 cat 7477–99 2.9 1.5 1.2 3.8
Hc-Cla-P89 cat 7143–7477, 1–99 12.6 3.5 10.9 1.0
Hpa-P89 cat 1–89 1.0 1.0 1.0 1.0
Enhancer clones
Xba-99 SVE cat 6133–99 37.7 13.4 38.1 14.0
Cla-Hpa SVE cat 7477–7946 1.9 1.7 6.4 4.9
7477–7758 nd nd 3.1 5.2
7758–7946 nd nd 0.4 1.3
Hc-Cla SVE cat 7143–7477 33.9 17.5 44.3 2.2
SVE cat None 1.0 1.0 1.0 1.0To evaluate steady-state BPV-1 mRNA levels in transiently
transfected NIH-3T3 cells, a subset of the clones in Fig. 1 was assayed
by RNAse protection (Haugen et al., 1988). P89-initiated mRNA
reached ∼11-fold higher levels with the full-length upstream
promoter fragment between nt 6946 and 99 than with a 5′ deletion
to nt 7477 (Fig. 2, compare lane a to lane b). Furthermore, the
upstream fragment (nt 7143–7477) linked to the minimal P89
promoter (+1 to +99) increased correctly initiated transcript levels
∼10 fold (Fig. 2, lane d versus lane c). The BPV-1 URR cis sequences
thus enhanced transcription at the authentic P89 promoter. The
sequences between nts 7477 and 7946, however, contributed to
activation because P89 activity was higher in the complete URR
construction (Fig. 2, lane a).
To further characterize the regulatory elements, multiple frag-
ments of the BPV-1 URR and late gene region were inserted upstream
or downstream of the enhancer-negative SV40 early promoter-driven
cat gene in pSVE-cat (Haugen et al., 1987). The resulting constructs
were assayed for CAT activity in transiently transfected NIH-3T3 cells
(Fig. 3). The entire URR with a part of the late region (nt 6133–99)
increased the activity of the SVE constructions ∼40-fold. Sequences
between nt 6698 and 6946 increased CAT activity when placed 3′ to
the SVE-cat unit, but not in the 5′ location. It is possible that these
sequences contain RNA processing signals for late gene transcripts
similar to those at the 3′ end of the early region (Baker and Noe, 1989)
rather than a classical transcriptional enhancer. In contrast, the
fragment between nt 7143 and 7351 activated CAT expression 12 to
44-fold in a position and orientation-independent manner. A smaller
fragment between nt 7143 and 7351 (Fig. 3) showed ∼30% less
activity, indicating that sequences between nt 7351 and 7477 contain
additional cis elements. Sequences between nt 7477 and 7946 also
increased pSVE-cat activity 6 to 10-fold in an orientation and position-
independent manner. Further deletions in this fragment led to
reduction of its activity, demonstrating that it also comprises multiple
regulatory elements.
Cell type speciﬁcity of BPV-1 cis elements
The BPV-1 genome replicates and is transcriptionally active in
ﬁbroblasts as well as in keratinocytes in bovine ﬁbropapillomas
(reviewed in Lambert et al., 1988; Turek et al., 1987). In contrast, BPV-
4 (Morgan et al., 1999; Vance et al., 1999) and HPV transcription is
restricted to keratinocytes and cervical carcinoma cells due to
enhancers that are preferentially active in these cell types (Cripe et
al., 1990; Cripe et al., 1987; Gius et al., 1988; Gloss et al., 1987; Swift et
al., 1987; Thierry and Yaniv, 1987). To determine whether BPV-1 P89
transcription reﬂected the extended viral host range, selected P89Human Monkey
carcinoma Fibroblast Keratinocyte Cervical
carcinoma
Hepatoma Kidney
GM3498 HaCaT HeLa SiHa HepG2 CV-1
2.6 1.0 60.9 34.5 1.7 2.8
nd 2.0 34.2 29.5 1.4 3.0
0.7 1.0 3.0 4.6 0.6 0.8
8.0 5.5 65.0 21.9 1.7 4.5
1.0 1.0 1.0 1.0 1.0 1.0
7.6 2.2 21.0 12.0 2.7 9.3
0.9 3.3 2.6 2.1 1.7 1.4
nd 3.0 2.1 4.0 3.2 nd
nd 2.0 0.8 0.6 0.8 nd
8.4 2.4 22.8 15.0 1.8 13.6
1.0 1.0 1.0 1.0 1.0 1.0
Fig. 4. TEF-1 binding is necessary for BPV-1 enhancer activation in vivo. (A) BPV-1 URR
contains TEF-1 binding sites. A fragment of BPV-1 URR DNA (nt 7142–7385) was 5′ end-
labeled on the lower strand and the binding of vaccinia-expressed TEF-1 protein (lanes
2, 3) or albumin control (lanes 1, 4) was determined by DNAse I footprinting as
described (Ishiji et al., 1992). The position of cleavage products was determined by
comparison with a sequencing reaction performed on the probe (not shown). (B) URR
cismutations reduce or abolish TEF-1 or Sp1 binding. Mobility shift results with double-
stranded 32P-labeled wt and mutant oligonucleotides (described in Table 2) using
puriﬁed TEF-1 (lanes 1–6) or Sp1 (lanes 7–9). Speciﬁc TEF-1 or Sp1 complexes are
indicated by arrows. (C) TEF-1 and Sp1 binding sitemutations decrease BPV-1 enhancer
activity. CAT activity of pSVE-cat reporter clones containing wt and mutant BPV-1
sequences (nt 7142–7385) in transiently transfected B1 bovine ﬁbroblasts relative to
pSVE-cat. Values are from duplicate cultures in two independent assays. (D)
Competition with TEF-1 motifs speciﬁcally inhibits BPV-1 activation. The reporter
plasmids, 9 μg, were cotransfected into HaCaT cells with 18 μg of the competitor plasmid
containing either eight copies of the wild-type or mutant TEF-1 enhansons, GTIICwt(R)
or GTIICmut(R) as indicated. The column labeled “none” contained 18 μg of pUC18 as
competitor. Relative CAT activities are expressed relative to the 2GTIIC(R)-tk-cat clone.
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keratinocytes and other epithelial cells of bovine, mouse, human and
monkey origin (Table 1).
The upstream enhancer fragment (nt 7143–7477) activated both
the P89 promoter and the SV40 early promoter 8 to 65-fold in most
cell types tested, including ﬁbroblasts as well as most epithelial cells,
except for the human hepatocarcinoma cell line, HepG2, and the
undifferentiated mouse teratocarcinoma cell line, F9 (Table 1). In
contrast, the promoter-proximal URR fragment (nt 7477–7946) was
most active in the mouse NIH-3T3 and F9 cells (6 and 5-fold,respectively) with less activity exhibited in other cell types. The BPV-1
cis elements therefore varied in activity among different types of cells
but showed an extended host range compared to the keratinocyte-
dependent enhancers of human papillomaviruses.
Cooperation of TEF-1 and Sp1 is required for full activity of the
upstream enhancer
TEF-1, a factor critical for the function of the HPV-16 E6–E7
promoter, is restricted to keratinocytes and cervical cancer cells (Ishiji
et al., 1992). However, TEF-1 also contributes to the activity of the
SV40 enhancer (Xiao et al., 1991) in a broad range of cells.
To test for possible binding of TEF-1 to BPV-1 URR cis elements,
we ﬁrst performed DNase I protection assays with puriﬁed TEF-1
expressed from recombinant vaccinia virus. No strong binding sites
were found in the proximal enhancer element (data not shown).
However, in the upstream fragment, TEF-1 binding strongly pro-
tected sequences between nt 7166–7189 and nt 7232–7256 (Fig. 4A).
The protection from DNase I digestion was eliminated by competition
with an oligonucleotide containing the SV40 TEF-1 site, GTIIC
(Table 2), but not by a mutant oligonucleotide (data not shown).
Thus, similar to HPV-16, TEF-1 speciﬁcally binds to sites within the
BPV-1 enhancer.
To test the functional role of these sites, we synthesized
oligonucleotides with mutations that alter the TEF-1 binding motifs
(Table 2). In addition, we mutated a region required for enhancer
activity in bovine ﬁbroblasts that had been proposed to bind Sp1
(Vande Pol and Howley, 1990). In mobility shift assays, the 32P-labeled
double-stranded wt oligonucleotide, BPV-1 nt 7196–7227, but not the
mutant sequence, formed a complex with puriﬁed Sp1 similar in
mobility to that with a control oligonucleotide containing an Sp1
binding site of the HSV-1 IE-3 promoter (Forsberg and Westin, 1991),
(Fig. 4B, lanes 7–9). TEF-1 site #1 or #2 mutations also reduced
binding of puriﬁed TEF-1 compared to wt motifs (Fig. 4B, lanes 1–6).
In competition experiments, the binding afﬁnity for the mutant TEF-
1#1 and TEF-1#2 sites was 3 and 5-fold lower, respectively, compared
to wt (data not shown).
To assess the role of Sp1 and TEF-1 binding in transcriptional
activation, the cis mutations were ﬁrst introduced singly or in
combination into the reporter clone 7143–7385 SVE-cat (depicted in
Fig. 3A), and the resulting constructs were transfected into B1 bovine
ﬁbroblasts (Fig. 4C). The mutation in the upstream TEF-1 site #1
reduced activity 3-fold while the mutations in the downstream TEF-1
site #2 further lowered reporter activity, albeit slightly (less than 2-
fold). The Sp1 site mutation reduced activity 6-fold. These data show
that mutations that alter the binding of TEF-1 and Sp1 decrease the
activity of the upstream enhancer element. The combination of
mutations had an additive effect, suggesting that activation requires
cooperation between TEF-1 and Sp1.
To conﬁrm that TEF-1 interaction in vivo with its cognate motifs is
necessary for activation, we tested the activity of the 7143–7385 SVE-
cat reporter clone in transfections with competitor plasmids carrying
multiple wild-type or mutant GTIIC enhansons of the SV40 enhancer
(Ishiji et al., 1992; Xiao et al., 1991). The prototype TEF-1-dependent
enhancer clone, 2GTIIC(R)-tk-cat (Fig. 4D, clone a), with four copies of
two closely spaced GTIIC enhansons, was active in HaCaT cells.
Cotransfection with excess wild-type GTIIC sequences reduced its
activity 3-fold, and the reporter plasmid containing the BPV-1 nt
7143–7385 enhancer element (Fig. 4D, clone b) was reduced 2.5 fold.
In contrast, cotransfection with the mutant GTIIC enhansons that do
not bind TEF-1 led to no reduction in activity, indicating that the wt,
but not the mutant GTIIC competitor speciﬁcally titrated active TEF-1
in the cells. In control experiments, the TEF-1-independent major
immediate early enhancer/promoter of human cytomegalovirus was
not inﬂuenced by excess quantities of competing TEF-1 sites (Fig. 4D,
clone c). Taken together, our mutagenesis and competition results
Table 2
Oligonucleotides used in this study.
Site Source or reference Sequencea
TEF-1 #1 wt BPV-1 nt 7165–7195 CACTTAATAGCAATGTGCTGTGTCAGTTGTT
Mutant CACTTAATAGCAcgtTGCTGTGTCAGTTGTT
Sp1 wt BPV-1 nt 7193–7125 GTTTATTGGAACCACACCCGGTACACATCCTGT
Mutant GTTTATTcGAACCctctCCGGTACACATCCTGT
TEF-1 #2 wt BPV-1 nt 7231–7253 ATTTGCAGTGCGTGCATTGAATT
Mutant ATTTGCAGTGCGTGacgTGAATT
GTIIC wt SV40 (Ishiji et al., 1992) CAGCTGTGGAATGTGTGTCAGTT
Sp1 HSV-1 IE-3 gene (Forsberg and Westin, 1991) ctagaaTATTCCGGCCCCGCCCATtctgtcb
a Lower case letters designate mutations or added cloning sites as indicated.
b Top strand of a double-stranded oligonucleotide with Xba I and Xho I compatible ends.
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BPV-1 in vivo.
TEF-1 and Sp1 binding to the 5’ sites is necessary for efﬁcient early gene
transcription and initial BPV plasmid ampliﬁcation
To test the role of enhancer activity on viral early gene transcrip-
tion, TEF-1 and Sp1 mutations were introduced into the plasmid BPV-
1/pML. This clone contains the entire BPV-1 genome and can stably
replicate in and transform mouse cells (Fig. 5A). Total RNA was
harvested 18 h after transfection of 3T3 cells with these plasmids. The
mutations in both of the TEF-1 sites or the Sp1 site reduced P89-
initiated transcripts by two and threefold, respectively, while a
construct with all three mutations (TEF-1/Sp1 mut) had 5-fold
lower activity (Fig. 5B). Thus, factor binding to these sites was
necessary for P89 activity in the context of the complete viral genome.
The Sp1 and TEF-1 mutations also affected the initial ampliﬁcation
of the BPV-1 plasmids. After transfection of mouse NIH 3T3 cells, BPV-
1 replication was assessed by the accumulation of BPV-1 DNA which
lost bacterial methylation and thus became resistant to Dpn IFig. 5. Activation of viral early gene transcription by cellular factors is limiting for BPV-1 p
transfectionwithwt andmutant BPV-1 genomes. (B) Mutations in TEF-1 and/or Sp1 sites in t
3T3 cells 24h after transfectionwithwt BPV-1/pML ormutants togetherwith pSV2-cat(Δ13) c
and cat (nt 69 to 1), digested byRNase and analyzedbydenaturing gel electrophoresis. Protect
by the arrows. (C) TEF-1 and/or Sp1 sitemutations reduce initial accumulation of BPV-1 plasm
harvested from the cultures at 18, 36, 60, 84 and 108 h, digested with Dpn I and HinD III, and
BPV-1 probe. The arrow indicates the migration position of replicated, Dpn I-resistant BPV-1
plasmid DNA. Lanes 1–5 were exposed for 24 h and lanes 6–20 for 48 h to visualize replicatdigestion (Fig. 5C). Although replication of BPV-1 sequences was
observed in all cases, mutations in the TEF-1 or Sp1 motifs or their
combination resulted in decreased BPV-1 DNA accumulation com-
pared to the wt after 108 h (2, 4 and 7-fold lower than wt DNA,
respectively).
Full enhancer activity is necessary for efﬁcient cell transformation and
establishment of replication but it does not control viral gene expression
or copy numbers of BPV-1 plasmid genomes in established transformants
Since the expression of viral early genes is a prerequisite of efﬁcient
transformation of C127 cells by BPV-1 we tested the wt and mutant
BPV-1 constructions in transformation assays. As shown in Fig. 6A,
compared to wt, the numbers of transformed cell foci observed with
the TEF-1 and Sp1 mutants were reduced 3 and 8-fold, respectively,
while the combined mutant was 12-fold lower, in agreement with
reduced expression of viral early genes in the mutants.
Because some replication-defective BPV-1 mutants have been
shown to integrate in transformed cells, we further analyzed wt and
mutant BPV-1 transformants to determine the physical state of virallasmid ampliﬁcation. (A) Experimental design for the evaluation of initial events after
he entire BPV-1 genome reduce P89 mRNA levels. Cellular RNAwas extracted fromNIH-
ontrol, hybridized to 32P-labeled antisense RNAprobes against BPV-1 P89 (nt 310 to nt 1)
ed bands of 221 nt for P89 and56 nt for the internalΔ13-cat control transcripts are shown
id DNA. After transfection of NIH-3T3 cells withwt ormutant BPV-1 plasmids, DNAwas
analyzed by agarose gel electrophoresis followed by Southern blot hybridization with a
DNA. The lower bands correspond to the Dpn-I digestion products derived from input
ed DNA.
Fig. 6. Cellular factors are not required for viral gene expression in persistent infection.
Cellular transformation by mutant BPV-1 genomes is reduced. C127 cells were
transfected with wt and mutant BPV-1/pML. The average focus-forming units/1 μg
BPV-1 clone DNA in duplicate C127I cultures in two experiments are shown. (B)
Established transformed cell clones harbor comparable levels of wt or mutant
extrachromosomal BPV-1 DNA. Uncut and DpnI/HindIII-digested DNAs from C127I
cultures transformed independently bywt or mutant BPV-1 were analyzed by Southern
blot hybridization. Uncut cellular DNAs were run next to 100 pg wt BPV-1/pML input
DNA (“control”). The same DNAs were also tested after digestionwith Dpn I and HinD III
(except in “control” where Dpn I was omitted). BPV-1 mutations in the transformants
were conﬁrmed by PCR and sequencing. (C) Transformed cell clones with wt and
mutant BPV-1 express comparable levels of P89 transcripts. RNA was extracted from
duplicate independent cultures of C127 cells transformed by wt or mutant BPV-1/pML,
and analyzed by RNase protection using 32P-labeled antisense RNA probes against BPV-
1 P89 (as illustrated in Figs. 2 and 5) or 28S ribosomal RNA. The protected bands of 221
nt for P89 and 115 nt for the 28 S ribosomal RNA control transcripts are shown. (D) wt
and mutant BPV-1 transformants express comparable levels of active E2 transactivator.
C127 cells or transformed cell clones were cotransfected with 1 μg of a baseline reporter
plasmid tk-cat, or the E2 responsive reporter pE2×2 tk-cat and with pCG E2 or pCG neo
as indicated. The CAT activity was determined as in Fig. 3. The E2 transactivation is
expressed as the ratio of the observed activities of the E2 responsive reporter plasmid to
non-responsive tk cat plasmid. A ratio of 1 indicates no E2 activity.
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or Sp1 sites persisted in all independently transformed cultures as
extrachromosomal, supercoiled circular plasmids (Fig. 6B and data not
shown). Furthermore, they were indistinguishable not only in
structural DNA forms but also in quantity (i.e. plasmid copy number
per cell) in the wt BPV-1 transformed cells (Fig. 6B, “uncut”). Analysis
of the DNA linearized with HinDIII (Fig. 6B, “digested”) showed,
within the limits of analysis by gel electrophoresis, no deleted or
rearranged forms with either wt or mutant viral genomes. Sequence
analysis of the enhancer URR region ampliﬁed by PCR from the
transformed cultures conﬁrmed that all replicating BPV-1 plasmids
retained the cis mutations of the input mutant constructs.
Furthermore, in contrast to the decreased levels of steady-state
P89 mRNA encoded by the BPV-1 mutants 18 h post-transfection,
multiple independent cultures transformed by wt BPV-1 or by the
TEF-1, Sp1 or TEF-1/Sp1 mutants expressed comparable P89-initiated
mRNA levels (Fig. 6C and additional data not shown). Thus, the effect
of mutations in the TEF-1 or Sp1 binding sites was to preferentially
interfere with viral transcription and DNA replication during the
establishment phase of infection, but not in established transformed
cells.
In agreement with this conclusion, we found that wt and mutant
BPV-1 transformants expressed comparable levels of functional E2
gene products (Fig. 6D). The E2 responsive promoter plasmid, E2×2
tk-cat, was activated 7 to 10-fold upon transfection in wt BPV-1 or
TEF-1/Sp1 mutant-harboring cell lines but not in uninfected C127
cells. Cotransfection with a plasmid expressing the BPV-1 E2
transactivator, pCG-E2, resulted not only in reporter activation in
uninfected C127 controls but also in further stimulation of reporter
activity in the wt and mutant BPV-1-expressing cell lines. This
observation demonstrated that both wt and mutant BPV-1-trans-
formed cells expressed comparable levels of active E2-TA. Taken
together, these results indicate that full transcriptional activation by
cellular factors interacting with the URR is not limiting for the
maintenance of viral gene expression or plasmid persistence in
established transformants.
Discussion
In this study, we examined the transcriptional regulation of BPV-1
early genes by cellular transcription factors. The BPV URR contains
regulatory elements that interact with viral and cellular factors as do
the URRs of HPV strains. In contrast to the restricted, epitheliotropic
host range of the HPV enhancers, activities of the BPV-1 URR elements
reﬂect the ability of the virus to persist in ﬁbroblasts. Full transcrip-
tional activation by cellular factors, TEF-1 and Sp1, was found to be
limiting during the establishment phase for the initial accumulation of
BPV-1 plasmid genomes and cell transformation but not required for
the maintenance of viral transcription or genome copy number in
BPV-1-transformed ﬁbroblasts.
Structure of BPV-1 URR
The URR of BPV-1 contains cis active sequences required for virus
gene expression, cell transformation and viral replication. Although
the URRs of both BPV and HPV have been known to contain multiple
conserved E2 binding motifs (Sanchez et al., 2008) that are required
for viral gene expression and replication (Haugen et al., 1987; Spalholz
et al., 1987) and (Lace et al., 2008b; Stubenrauch et al., 1998), they also
respond to regulation by cellular transcription factors. We identiﬁed
multiple fragments spanning the BPV-1 late gene region and URR that
can independently inﬂuence transcription in cis. The URR fragment
between BPV-1 nt 7143 and 7477 was a strong enhancer in ﬁbroblasts
as well as in most other cell types while the nt 7477–7946 segment
was preferentially active in some but not all cells of epithelial origin.
We have shown that cellular factors Sp1 and TEF-1 are both necessary
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1996) was previously identiﬁed as a factor critical for the function of
the HPV-16 E6–E7 promoter in keratinocytes and cervical cancer cells
(Ishiji et al., 1992). TEF-1 also contributes to the function of a broadly-
active SV40 enhancer (Xiao et al., 1991). It is possible that TEF-1,
together with or independent of related factors (e.g. TEF-3, TEF-4 and
AP-2), mediates the activation of enhancers in different cells. In
addition to the three Sp1 motifs deﬁned previously (Sandler et al.,
1996), URR sequences proximal to the P89 promoter also appear to
interact with multiple cellular factors as shown by deletion mutagen-
esis (this study). For example, a binding site for transcription factor
AP-2 has been demonstratedwithin this proximal segment, by DNase I
footprint analysis (Imagawa et al., 1987). However, only imperfect
matches were identiﬁed for additional putative AP-2 consensus
motifs.
It is likely that overall BPV enhancer activity reﬂects cooperative
interactions of TEF-1 and Sp1 with other, as yet undeﬁned factors. We
predict that these factors differ from those that restrict the transcrip-
tion of HPV E6–E7 promoters to keratinocytes and cervical carcinoma
cells. The identiﬁcation of such factors will require further mutagen-
esis and in vitro DNA binding assays to deﬁne these functional
differences.
Role of cellular transcription factors in the establishment of
papillomaviral infection
Since the binding of papillomaviral particles to cells appears to lack
tissue speciﬁcity (Müller et al., 1995; Roden et al., 1994; Volpers et al.,
1995), transcription is dependent on cell factors that vary between cell
types and may provide a mechanism for the restriction of viral
infection to speciﬁc tissues. Consistent with this model, the ability of
BPV-1 to establish viral gene expression and DNA replication in both
epithelial and ﬁbroblastic cells is reﬂected by the observed activity of
its URR segments in a variety of cell types.
Role of cellular transcription factors in BPV-1 plasmid maintenance
BPV URR segments also contain multiple binding sites for the viral
transcription factor E2. These sites are required for transcription
activation as well as plasmid maintenance by E2 gene products. Once
BPV replication is established, E2 isoforms will be present within the
cell that may regulate transcription from P89 and other viral
promoters. Since transformed cultures derived from wt and mutant
BPV-1 genomes exhibited similar ranges of replicating plasmid BPV-1
DNA and P89 mRNA levels, we conclude that the critical transcription
activation functions of TEF-1 and Sp1 at the upstream URR segment
are replaced by other cellular and viral factors, including forms of the
viral activator protein E2. Similar levels of E2 transactivation activity
detected in cell lines transformedwithwt andmutant BPV-1 genomes
support this concept.
However, cellular factors are nonetheless critical in the main-
tenance of BPV-1 persistence; for example, the E2-TA activates
transcription in cooperation with Sp1 and other cellular transcription
factors (Steger et al., 1996; Ushikai et al., 1994). In HPV-16 and other
mucosal HPVs, the proximal E2 sites mediate transcriptional repres-
sion at the E6 promoter by limiting levels of E2-TA and E8^E2. This
repression is required for maintenance of papillomaviral replication
and limits initial plasmid ampliﬁcation (Lace et al., 2008a, 2008b).
This suggests a mechanism for negative feedback control of early gene
synthesis is critical for HPV infection. In BPV-1, E2-TA is thought to
activate all early region promoters (Szymanski and Stenlund). Since
the plasmid levels and P89 mRNA levels are similar for BPV wt and
mutant cell lines (this study), it suggests that a mechanism to limit
replication and transcription is also present in BPV-1. Although it is
not clear how this modulation may occur in BPV-1, regulation by E2
repressor forms appears to play a role since E2 mutant genomes areunable to replicate in stably transformed cultures (Choe et al., 1989;
Lambert et al., 1990; Riese et al., 1990).
Materials and methods
Plasmid constructions
Molecular cloning followed established protocols (Cripe et al.,
1987; Haugen et al., 1987; Haugen et al., 1988; Ushikai et al., 1994). The
plasmid constructions are illustrated in the respective ﬁgures.
Restriction enzyme fragments of BPV-1 DNA are numbered by the
ﬁrst nucleotide of the endonuclease recognition site (Haugen et al.,
1987; Haugen et al., 1988). BPV-1 promoters are designated by the
nucleotide coordinates of their major transcription start site (Ahola et
al., 1987; Baker and Howley, 1987; Stenlund et al., 1985); their
alternative names, P1 through P5 (Choe et al., 1989; Stenlund and
Botchan, 1990; Stenlund et al., 1987), are given in the Introduction.
The precursor plasmid to the chloramphenicol acetyl transferase
(cat) reporter clones was pSVE-cat (Cripe et al., 1987; Haugen et al.,
1987; Haugen et al., 1988; Ushikai et al., 1994). Restriction fragments
of the BPV-1 URR were inserted into upstream or downstream
polylinker restriction sites. The pP89-cat deletion mutants were
described previously (Haugen et al., 1987) or constructed by deletions
or insertions in pP89-cat. Binding motif mutations were introduced
into reporter clones or BPV-1/pML plasmids via a two-stage
polymerase chain reaction (PCR) method with oligonucleotides
containing 3 nt substitutions listed in Table 2 (Ishiji et al., 1992;
Ushikai et al., 1994). The pMSV-E2, pCG-neo, pCG-E2, ptk-cat, and
pE2×2tk-cat clones were as described (Haugen et al., 1987). All
molecular constructions were veriﬁed by DNA sequencing.
Cells and transfections
The bovine embryo ﬁbroblast strain B1 and the bovine breast duct
epithelial cell line BMGE (Schmid et al., 1983) were a kind gift of Drs.
M. Blessing and W. Franke, German Cancer Research Center, Heidel-
berg, Germany. HaCaT, a spontaneously immortalized human kerati-
nocyte cell line that retains its capacity for in vivo differentiation
(Boukamp et al., 1988), was a kind gift from Drs. P. Boukamp and N.
Fusenig, German Cancer Research Center, Heidelberg, Germany.
Human ﬁbroblasts (strain GM3498) were from the American Type
Culture Collection, Rockville, MD. All cell cultures were grown in
Dulbecco's MEM with 7% iron-supplemented newborn calf and 1%
fetal calf serum except for NIH-3T3 cells in which the fetal calf serum
was omitted. All cells, except the HaCaT line, were transfected in
duplicate by calcium phosphate coprecipitation followed by glycerol
or DMSO treatment 4 to 6 h later (Cripe et al., 1987). HaCaT cells were
transfected by lipofection (BRL/Gibco, Gaithersburg, MD). To assess
transfection efﬁciency, control cat plasmids driven by the SV40
promoter-enhancer or the murine sarcoma virus LTR were included
in each transfection experiment. Enzymatic CAT assays and RNase
protection assays were performed as described (Cripe et al., 1987;
Haugen et al., 1988). The 28S rRNA probe was transcribed from the
plasmid template pTRI-RNA-28S (Ambion, Austin, TX).
Transformation and replication assays
Transformed foci of C127I cells were scored 2–3 weeks after
transfection with wt BPV-1/pML or mutant plasmids (Haugen et al.,
1987). For all replication assays, DNAswere extracted from transfected
NIH 3T3 cells or from transformed C127I cells and analyzed by agarose
gel electrophoresis and alkaline Southern blot transfer onto posi-
tively-charged Nylon membranes (Zeta-probe, Bio-Rad, Hercules, CA)
as described (Ustav and Stenlund, 1991). Probes were generated by
random priming using α-32P-labeled dCTP and dATP with BPV-1/pML
DNA as a substrate.
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The substrate for footprinting experiments was a DNA fragment of
the BPV-1 regulatory region, nt 7142–7385, 5′ end-labeled using T4
polynucleotide kinase. Reaction mixtures containing vaccinia-
expressed TEF-1 protein were preincubated at 30 °C for 10 min in a
ﬁnal volume of 50 μl and processed as described (Ishiji et al., 1992).
Mobility shift assays
Oligonucleotides used as probes and competitors are shown in
Table 2. Bindingwas performed in a 25 μl reaction volume as described
(Ishiji et al., 1992) with DNA afﬁnity-puriﬁed TEF-1 protein from
HaCaT nuclear extracts or recombinant Sp1 (Promega) and
15,000 cpm (∼4–8 fmol) of 32P-labeled double-stranded oligonucleo-
tide probe in the presence of 30–100 ng of poly(dI-dC) (Pharmacia) at
30 °C for 30 min. Protein–DNA complexes were resolved from the
unbound probe on non-denaturing 6% acrylamide gels and visualized
by autoradiography.
Acknowledgments
The authors thank M. Blessing, P. Boukamp, W. Franke, and N.
Fusenig for cells, and J. Carl for graphics, and A. Fulton for critical
reading of the manuscript. We also thank S. Parkinnen for assistance
with footprinting analyses.
This work was supported by the Department of Veterans Affairs (T.
H.H. and L.P.T.), and the University of Iowa Diabetes and Endocrinol-
ogy Research Center (L.P.T.).
References
Ahola, H., Stenlund, A., Moreno Lopez, J., Pettersson, U., 1987. Promoters and processing
sites within the transforming region of bovine papillomavirus type 1. J. Virol. 61,
2240–2244.
Baker, C.C., Howley, P.M., 1987. Differential promoter utilization by the bovine
papillomavirus in transformed cells and productively infected wart tissues. EMBO
J. 6, 1027–1035.
Baker, C.C., Noe, J.S., 1989. Transcriptional termination between bovine papillomavirus
type 1 (BPV-1) early and late polyadenylation sites blocks late transcription in BPV-
1-transformed cells. J. Virol. 63, 3529–3534.
Bernard, H.U., Apt, D., 1994. Transcriptional control and cell type speciﬁcity of HPV gene
expression. Arch. Dermatol. 130, 210–215.
Boukamp, P., Petrussevska, R.T., Breitkreutz, D., Hornung, J., Markham, A., Fusenig, N.E.,
1988. Normal keratinization in a spontaneously immortalized aneuploid human
keratinocyte cell line. J. Cell Biol. 106, 761–771.
Campo, M.S., Spandidos, D.A., Lang, J., Wilkie, N.M., 1983. Transcriptional control signals
in the genome of bovine papillomavirus type 1. Nature 303, 77–80.
Chin, M.T., Hirochika, R., Hirochika, H., Broker, T.R., Chow, L.T., 1988. Regulation of
human papillomavirus type 11 enhancer and E6 promoter by activating and
repressing proteins from the E2 open reading frame: functional and biochemical
studies. J. Virol. 62, 2994–3002.
Choe, J., Vaillancourt, P., Stenlund, A., Botchan, M., 1989. Bovine papillomavirus type 1
encodes two forms of a transcriptional repressor: structural and functional analysis
of new viral cDNAs. J. Virol. 63, 1743–1755.
Cripe, T.P., Haugen, T.H., Turk, J.P., Tabatabai, F., Schmid, P.G., Dürst, M., Gissmann, L.,
Roman, A., Turek, L.P., 1987. Transcriptional regulation of the human papilloma-
virus-16 E6–E7 promoter by a keratinocyte-dependent enhancer, and by viral E2
trans-activator and repressor gene products: implications for cervical carcinogen-
esis. EMBO J. 6, 3745–3753.
Cripe, T.P., Alderborn, A., Anderson, R.D., Parkkinen, S., Bergman, P., Haugen, T.H.,
Pettersson, U., Turek, L.P., 1990. Transcriptional activation of the human papillo-
mavirus-16 P97 promoter by an 88-nucleotide enhancer containing distinct cell-
dependent and AP-1-responsive modules. New. Biol. 2, 450–463.
DiMaio, D., 1991. Transforming activity of bovine and human papillomaviruses in
cultured cells. Adv. Cancer Res. 56, 133–159.
Dvoretzky, I., Shober, R., Chattopadhyay, S.K., Lowy, D.R., 1980. A quantitative in vitro
focus assay for bovine papilloma virus. Virology 103, 369–375.
Forsberg, M., Westin, G., 1991. Enhancer activation by a single type of transcription
factor shows cell type dependence. EMBO J. 10, 2543–2551.
Gius, D., Grossman, S., Bedell, M.A., Laimins, L.A., 1988. Inducible and constitutive
enhancer domains in the noncoding region of human papillomavirus type 18.
J. Virol. 62, 665–672.
Gloss, B., Bernard, H.U., Seedorf, K., Klock, G., 1987. The upstream regulatory region of
the human papilloma virus-16 contains an E2 protein-independent enhancer which
is speciﬁc for cervical carcinoma cells and regulated by glucocorticoid hormones.
EMBO J. 6, 3735–3743.Haugen, T.H., Cripe, T.P., Ginder, G.D., Karin, M., Turek, L.P., 1987. Trans-activation of an
upstream early gene promoter of bovine papilloma virus-1 by a product of the viral
E2 gene. EMBO J. 6, 145–152.
Haugen, T.H., Turek, L.P., Mercurio, F.M., Cripe, T.P., Olson, B.J., Anderson, R.D., Seidl, D.,
Karin, M., Schiller, J., 1988. Sequence-speciﬁc and general transcriptional activation
by the bovine papillomavirus-1 E2 trans-activator require an N-terminal amphi-
pathic helix-containing E2 domain. EMBO J. 7, 4245–4253.
Imagawa, M., Chiu, R., Karin, M., 1987. Transcription factor AP-2 mediates induction by
two different signal-transduction pathways: protein kinase C and cAMP. Cell 51,
251–260.
Ishiji, T., Lace, M.J., Parkkinen, S., Anderson, R.D., Haugen, T.H., Cripe, T.P., Xiao, J.H.,
Davidson, I., Chambon, P., Turek, L.P., 1992. Transcriptional enhancer factor (TEF)-1
and its cell-speciﬁc co-activator activate human papillomavirus-16 E6 and E7
oncogene transcription in human keratinocytes and cervical carcinoma cells. EMBO
J. 11, 2271–2281.
Jacquemin, P., Hwang, J.J., Martial, J.A., Dolle, P., Davidson, I., 1996. A novel family of
developmentally regulated mammalian transcription factors containing the TEA/
ATTS DNA binding domain. J. Biol. Chem. 271, 21775–21785.
Lace, M.J., Anson, J.R., Thomas, G.S., Turek, L.P., Haugen, T.H., 2008a. The E8^E2 gene
product of human papillomavirus type 16 represses early transcription and
replication but is dispensable for viral plasmid persistence in keratinocytes.
J. Virol. 82 (21), 10841–10853.
Lace, M.J., Anson, J.R., Turek, L.P., Haugen, T.H., 2008b. Functional mapping of the human
papillomavirus type 16 E1 cistron. J. Virol. 82 (21), 10724–10734.
Lambert, P.F., 1991. Papillomavirus DNA replication. J. Virol. 65, 3417–3420.
Lambert, P.F., Baker, C.C., Howley, P.M., 1988. The genetics of bovine papillomavirus type
1. Annu. Rev. Genet. 22, 235–258.
Lambert, P.F., Monk, B.C., Howley, P.M., 1990. Phenotypic analysis of bovine
papillomavirus type 1 E2 repressor mutants. J. Virol. 64, 950–956.
Lancaster, W.D., 1981. Apparent lack of integration of bovine papillomavirus DNA in
virus-induced equine and bovine tumor cells and virus-transformed mouse cells.
Virology 108, 251–255.
Law, M.F., Lowy, D.R., Dvoretzky, I., Howley, P.M., 1981. Mouse cells transformed by
bovine papillomavirus contain only extrachromosomal viral DNA sequences. Proc.
Natl. Acad. Sci. U. S. A. 78, 2727–2731.
Linz, U., Baker, C.C., 1988. Promoters of bovine papillomavirus type 1: in vitro activity
and utilization. J. Virol. 62, 2537–2543.
Lowy, D.R., Dvoretzky, I., Shober, R., Law, M.F., Engel, L., Howley, P.M., 1980. In vitro
tumorigenic transformation by a deﬁned sub-genomic fragment of bovine
papilloma virus DNA. Nature 287, 72–74.
Meyers, C., Frattini, M.G., Hudson, J.B., Laimins, L.A., 1992. Biosynthesis of human
papillomavirus from a continuous cell line upon epithelial differentiation. Science
257, 971–973.
Morgan, I.M., Grindlay, G.J., Campo, M.S., 1999. The bovine papillomavirus type 4 long
control region contains an epithelial speciﬁc enhancer. J. Gen. Virol. 80, 23–27.
Müller, M., Gissmann, L., Cristiano, R.J., Sun, X.Y., Frazer, I.H., Jenson, A.B., Alonso, A.,
Zentgraf, H., Zhou, J., 1995. Papillomavirus capsid binding and uptake by cells from
different tissues and species. J. Virol. 69, 948–954.
Ozbun, M.A., Meyers, C., 1998. Temporal usage of multiple promoters during the life
cycle of human papillomavirus type 31b. J. Virol. 72, 2715–2722.
Rando, R.F., Lancaster, W.D., Han, P., Lopez, C., 1986. The noncoding region of HPV-
6vc contains two distinct transcriptional enhancing elements. Virology 155,
545–556.
Riese, D., Settleman, J., Neary, K., DiMaio, D., 1990. Bovine papillomavirus E2 repressor
mutant displays a high-copy-number phenotype and enhanced transforming
activity. J. Virol. 64, 944–949.
Roden, R.B.S., Kirnbauer, R., Jenson, A.B., Lowy, D.R., Schiller, J.T., 1994. Interaction of
papillomaviruses with the cell surface. J. Virol. 68, 7260–17266.
Sanchez, I.E., Dellarole, M., Gaston, K., de Prat Gay, G., 2008. Comprehensive comparison
of the interaction of the E2 master regulator with its cognate target DNA sites in 73
human papillomavirus types by sequence statistics. Nucleic Acids Res. 36 (3),
756–769.
Sandler, A.B., Baker, C.C., Spalholz, B.A., 1996. Sp1 is critical for basal and E2-
transactivated transcription from the bovine papillomavirus type 1 P89 promoter.
J. Gen. Virol. 77, 189–198.
Schmid, E., Schiller, D.L., Grund, C., Stadler, J., Franke, W.W., 1983. Tissue type-speciﬁc
expression of intermediate ﬁlament proteins in a cultured epithelial cell line from
bovine mammary gland. J. Cell Biol. 96, 37–50.
Spalholz, B.A., Lambert, P.F., Yee, C.L., Howley, P.M., 1987. Bovine papillomavirus
transcriptional regulation: localization of the E2-responsive elements of the long
control region. J. Virol. 61, 2128–2137.
Spalholz, B.A., Vande Pol, S.B., Howley, P.M., 1991. Characterization of the cis elements
involved in basal and E2-transactivated expression of the bovine papillomavirus
P2443 promoter. J. Virol. 65, 743–753.
Steger, G., Ham, J., Yaniv, M., 1996. E2 proteins: modulators of papillomavirus
transcription and replication. Methods Enzymol. 274, 173–185.
Stenlund, A., Botchan, M.R., 1990. The E2 trans-activator can act as a repressor by
interfering with a cellular transcription factor. Genes Dev. 4, 123–136.
Stenlund, A., Bream, G.L., Botchan, M.R., 1987. A promoter with an internal regulatory
domain is part of the origin of replication in BPV-1. Science 236, 1666–1671.
Stenlund, A., Zabielski, J., Ahola, H., Moreno Lopez, J., Pettersson, U., 1985. Messenger
RNAs from the transforming region of bovine papilloma virus type I. J. Mol. Biol. 182,
541–554.
Stubenrauch, F., Lim, H.B., Laimins, L.A.,1998. Differential requirements for conserved E2
binding sites in the life cycle of oncogenic human papillomavirus type 31. J. Virol.
72, 1071–1077.
90 T.H. Haugen et al. / Virology 389 (2009) 82–90Swift, F.V., Bhat, K., Younghusband, H.B., Hamada, H., 1987. Characterization of a cell
type-speciﬁc enhancer found in the human papilloma virus type 18 genome. EMBO
J. 6, 1339–1344.
Szymanski, P., Stenlund, A., 1991. Regulation of early gene expression from the bovine
papillomavirus genome in transiently transfected C127 cells. J. Virol. 65, 5710–5720.
Thierry, F., Yaniv, M., 1987. The BPV1-E2 trans-acting protein can be either an activator
or a repressor of the HPV18 regulatory region. EMBO J. 6, 3391–3397.
Turek, L.P., Smith, E.M., 1996. The genetic program of genital human papillomaviruses in
infection and cancer. [Review] [151 refs]. Obstet. Gynecol. Clin. North Am. 23,
735–758.
Turek, L.P., Byrne, J.C., Lowy, D.R., Dvoretzky, I., Friedman, R.M., Howley, P.M., 1982.
Interferon induces morphologic reversion with elimination of extrachromosomal
viral genomes in bovine papillomavirus-transformed mouse cells. Proc. Natl. Acad.
Sci. U. S. A. 79, 7914–7918.
Turek, L.P., Haugen, T.H., Syrjanen, K., Gissmann, L., and Koss, L., (1987). In
“Transforming and regulatory functions of bovine papillomavirus type 1”, pp.
409–442. Springer, Heidelberg New York Tokyo.
Ushikai, M., Lace, M.J., Yamakawa, Y., Kono, M., Anson, J., Ishiji, T., Parkkinen, S., Wicker,
N., Valentine, M.E., Davidson, I., Turek, L.P., Haugen, T.H., 1994. trans activation bythe full-length E2 proteins of human papillomavirus type 16 and bovine
papillomavirus type 1 in vitro and in vivo: cooperation with activation domains of
cellular transcription factors. J. Virol. 68, 6655–6666.
Ustav, M., Stenlund, A., 1991. Transient replication of BPV-1 requires two viral
polypeptides encoded by the E1 and E2 open reading frames. EMBO J. 10, 449–457.
Vance, K.W., Campo, M.S., Morgan, M., 1999. An enhanced epithelial response of a
papillomavirus promoter to transcriptional activators. J. Biol. Chem. 274,
27839–27844.
Vande Pol, S.B., Howley, P.M., 1990. A bovine papillomavirus constitutive enhancer is
negatively regulated by the E2 repressor through competitive binding for a cellular
factor. J. Virol. 64, 5420–5429.
Vande Pol, S.B., Howley, P.M., 1992. The bovine papillomavirus constitutive enhancer is
essential for viral transformation, DNA replication, and the maintenance of latency.
J. Virol. 66, 2346–2358.
Volpers, C., Unckell, F., Schirmacher, P., Streeck, R.E., Sapp, M., 1995. Binding and
internalization of human papillomavirus type 33 virus-like particles by eukaryotic
cells. J. Virol. 69, 3258–3264.
Xiao, J.H.,Davidson, I.,Matthes,H., Garnier, J.M., Chambon, P.,1991. Cloning, expression, and
transcriptional properties of the human enhancer factor TEF-1. Cell 65, 551–568.
